A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 287-293

  Davidson, Jaime ^a   Koro, Carol ^b,c   Arondekar, Bhakti ^b   Lee, Bo Hyen ^b   Fedder, Donald ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

antidiabetic agents; FPG; HbA1c; therapy change

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DATABASES AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 41549120982     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.02.007     Document Type: Article

References (19)

1. Did you know? [International Diabetes Federation Web site]. http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A Accessed September 22, 2006
2. King H., Aubert R., and Herman W. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
3. World Health Organization Diabetes Programme. Country and regional data: World [WHO Web site]. http://www.who.int/diabetes/facts/world_figures/en/ Accessed September 22, 2006
4. Hogan P., Dall T., Nikolov P., and American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
5. Narayan K., Boyle J., Geiss L., et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 29 (2006) 2114-2116
6. Gilmer T., O'Connor P., Manning W., and Rush W. The cost to health plans of poor glycemic control. Diabetes Care 20 (1997) 1847-1853
7. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
8. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf Accessed September 22, 2006
9. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
10. Weissman P., Goldstein B., Rosenstock J., et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: The EMPIRE Study. Curr Med Res Opin 21 (2005) 2029-2035
11. Grant R., Cagliero E., Dubey A., et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. DiabetMed 21 (2004) 150-155
12. Brown J., Nichols G., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
13. Yood M., Lafata J., Koro C., et al. Time to pharmacotherapy change in response to elevated HbA1c test results. Curr Med Res Opin 22 (2006) 1567-1574
14. Griffis D., McLaughlin T., Dirani R., and Thwaites R. An observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practice. Curr Ther Res Clin Exp 65 (2004) 149-160
15. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
16. Phillips L., Branch W., Cook C., et al. Clinical inertia. Ann Intern Med 135 (2001) 825-834
17. Wetzler H., and Snyder J. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care 23 (2000) 1637-1641
18. Shah B., Hux J., Laupacis A., et al. Clinical inertia in response to inadequate glycemic control: Do specialists differ from primary care physicians?. Diabetes Care 28 (2005) 600-606
19. Wagner E., Sandhu N., Newton K., et al. Effect of improved glycemic control on health care costs and utilization. JAMA 285 (2001) 182-189